Cargando…

98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia

Immunoglobulin heavy chain variable region (IGHV) mutational status has been an important prognostic factor for chronic lymphocytic leukemia (CLL) for decades. Patients with unmutated IGHV (≥98% identity to the germline sequence) have inferior prognosis and tend to carry unfavorable genetic markers...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Ke, Sun, Qian, Qiao, Chun, Zhu, Huayuan, Wang, Li, Wu, Jiazhu, Wang, Lili, Fu, Jianxin, Young, Ken H., Fan, Lei, Xia, Yi, Xu, Wei, Li, Jianyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997101/ https://www.ncbi.nlm.nih.gov/pubmed/31849198 http://dx.doi.org/10.1002/cam4.2788

Ejemplares similares

NOTCH1 mutation and its prognostic significance in Chinese chronic lymphocytic leukemia: a retrospective study of 317 cases
por: Zou, Yixin, et al.
Publicado: (2018)

Normal serum protein electrophoresis and mutated IGHV genes detect very slowly evolving chronic lymphocytic leukemia patients
por: Chauzeix, Jasmine, et al.
Publicado: (2018)

MYD88 mutations predict unfavorable prognosis in Chronic Lymphocytic Leukemia patients with mutated IGHV gene
por: Qin, Shu-Chao, et al.
Publicado: (2017)

HELQ and EGR3 expression correlate with IGHV mutation status and prognosis in chronic lymphocytic leukemia
por: Guo, Chao, et al.
Publicado: (2021)

IGHV-associated methylation signatures more accurately predict clinical outcomes of chronic lymphocytic leukemia patients than IGHV mutation load
por: Hussmann, Dianna, et al.
Publicado: (2021)

Downregulation of circ_0132266 in chronic lymphocytic leukemia promoted cell viability through miR-337-3p/PML axis
por: Wu, Wei, et al.
Publicado: (2019)

Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia
por: Kaufman, Matthew, et al.
Publicado: (2022)

PB1869: IGHV REPERTOIRE FEATURES IN KAZAKHSTAN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
por: Klodzinskiy, A., et al.
Publicado: (2022)

Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia
por: Heerema, Nyla A., et al.
Publicado: (2020)

PB1946: NOTCH PATHWAY MUTATION CONTRIBUTES TO INFERIOR PROGNOSIS IN HBV-INFECTED CHRONIC LYMPHOCYTIC LEUKEMIA
por: Shang, Chunyu, et al.
Publicado: (2023)

Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV—Unmutated Chronic Lymphocytic Leukemia
por: Maharaj, Dipnarine, et al.
Publicado: (2020)

Dichotomous and stable gamma delta T-cell number and function in healthy individuals
por: Ou, Lingling, et al.
Publicado: (2021)

Combined Patterns of IGHV Repertoire and Cytogenetic/Molecular Alterations in Monoclonal B Lymphocytosis versus Chronic Lymphocytic Leukemia
por: Henriques, Ana, et al.
Publicado: (2013)

The Number of Overlapping AID Hotspots in Germline IGHV Genes Is Inversely Correlated with Mutation Frequency in Chronic Lymphocytic Leukemia
por: Yuan, Chaohui, et al.
Publicado: (2017)

High LEF1 expression predicts adverse prognosis in chronic lymphocytic leukemia and may be targeted by ethacrynic acid
por: Wu, Wei, et al.
Publicado: (2016)

Overexpression of c-Myc-dependent heterogeneous nuclear ribonucleoprotein A1 promotes proliferation and inhibits apoptosis in NOTCH1-mutated chronic lymphocytic leukemia cells
por: Zou, Yixin, et al.
Publicado: (2022)

Identifying a novel ferroptosis-related prognostic score for predicting prognosis in chronic lymphocytic leukemia
por: Pan, Bihui, et al.
Publicado: (2022)

High CXCR3 on Leukemic Cells Distinguishes IgHV(mut) from IgHV(unmut) in Chronic Lymphocytic Leukemia: Evidence from CD5(high) and CD5(low) Clones
por: Manukyan, Gayane, et al.
Publicado: (2020)

The pyroptosis-related gene signature predicts prognosis and indicates the immune microenvironment status of chronic lymphocytic leukemia
por: Sha, Yeqin, et al.
Publicado: (2022)

LncRNA NEAT1 promotes glioma cancer progression via regulation of miR-98-5p/BZW1
por: Li, Yabin, et al.
Publicado: (2021)

NOTCH1 Activation Negatively Impacts on Chronic Lymphocytic Leukemia Outcome and Is Not Correlated to the NOTCH1 and IGHV Mutational Status
por: Baldoni, Stefano, et al.
Publicado: (2021)

PB1957: PROGNOSTIC SIGNIFICANCE OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH IGHV-U IN THE ERA OF NOVEL AGNETS; REAL-LİFE DATA
por: Arikan, Fatma, et al.
Publicado: (2023)

Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHV(mut) and IgHV(unmut) subgroups
por: Burns, A, et al.
Publicado: (2018)

Identity by descent and association analysis of dichotomous traits based on large pedigrees
por: Liu, Tian, et al.
Publicado: (2011)

Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies
por: Poussin, Mathilde, et al.
Publicado: (2021)

Erratum: Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHV(mut) and IgHV(unmut) subgroups
por: Burns, A, et al.
Publicado: (2017)

Correction: Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHV(mut) and IgHV(unmut) subgroups
por: Burns, A, et al.
Publicado: (2019)

IGHV mutational status and outcome for patients with chronic lymphocytic leukemia upon treatment: a Danish nationwide population-based study
por: Rotbain, Emelie Curovic, et al.
Publicado: (2020)

Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia
por: Hengeveld, P. J., et al.
Publicado: (2023)

Long‐term molecular remission in a patient with acute myeloid leukemia harboring a new NUP98‐LEDGF rearrangement
por: Gallego Hernanz, Maria Pilar, et al.
Publicado: (2019)

Antitumor activity of an anti‐CD98 antibody
por: Hayes, Gregory M., et al.
Publicado: (2015)

Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open‐label phase 3 study
por: Huang, Xiaojun, et al.
Publicado: (2018)

Chinese language teachers’ dichotomous identities when teaching ingroup and outgroup students
por: Chen, Haijiao, et al.
Publicado: (2022)

IGHV1-69-Encoded Antibodies Expressed in Chronic Lymphocytic Leukemia React with Malondialdehyde–Acetaldehyde Adduct, an Immunodominant Oxidation-Specific Epitope
por: Que, Xuchu, et al.
Publicado: (2013)

Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course
por: Bagnara, Davide, et al.
Publicado: (2021)

Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV
por: Klausen, Uffe, et al.
Publicado: (2022)

Corticostriatal Projection Neurons – Dichotomous Types and Dichotomous Functions
por: Reiner, Anton, et al.
Publicado: (2010)

Evidence of somatic hypermutation in the antigen binding sites of patients with CLL harboring IGHV genes with 100% germline identity
por: Sofou, Electra, et al.
Publicado: (2022)

Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans
por: Xia, Yi, et al.
Publicado: (2014)

P634: EARLY-STAGE MEASURABLE RESIDUAL DISEASE DYNAMICS AND IGHV REPERTOIRE RECONSTITUTION DURING VENETOCLAX AND OBINUTUZUMAB TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Hengeveld, Paul, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ttlmf18od5ktun8lu2rod7vm7f